MedPath

FDA Approves BridgeBio's Drug for Rare Heart Condition, Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

• The FDA has approved BridgeBio's drug for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and often fatal heart condition. • This approval marks a significant advancement in treating ATTR-CM, offering a new therapeutic option for patients with this disease. • The drug targets the underlying cause of ATTR-CM, aiming to stabilize transthyretin and prevent amyloid fibril formation in the heart. • The approval is based on clinical trial data demonstrating the drug's efficacy and safety in improving outcomes for ATTR-CM patients.

BridgeBio has received FDA approval for its drug targeting transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and potentially fatal heart condition. This approval marks a significant milestone in the treatment of ATTR-CM, offering a new therapeutic option for patients affected by this debilitating disease.
ATTR-CM is characterized by the accumulation of misfolded transthyretin (TTR) protein as amyloid fibrils in the heart, leading to heart failure and other serious complications. The approved drug is designed to stabilize the TTR protein, preventing its misfolding and subsequent amyloid fibril formation.
The FDA's decision was based on data from pivotal clinical trials demonstrating the drug's efficacy and safety. These trials evaluated the drug's impact on key clinical endpoints, including survival, cardiovascular function, and quality of life. Detailed results from these trials will be crucial in understanding the full clinical benefit of the new therapy.
This approval addresses a significant unmet need in the treatment of ATTR-CM. While other therapies exist, they may not be suitable for all patients or may have limitations in their effectiveness. BridgeBio's new drug offers a promising alternative that targets the underlying cause of the disease.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves BridgeBio's Attruby (acoramidis) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved BridgeBio's Attruby (acoramidis) for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening heart condition.
Attruby is the first and only approved treatment that specifies near-complete stabilization of transthyretin (TTR), addressing the root cause of ATTR-CM.

FDA Approves BridgeBio's Attruby (acoramidis) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
Attruby is the first approved therapy with a label indicating near-complete transthyretin (TTR) stabilization, aiming to reduce cardiovascular deaths and hospitalizations associated with ATTR-CM.

FDA Approves BridgeBio's Attruby for Transthyretin Amyloid Cardiomyopathy

The FDA has approved BridgeBio's Attruby, an oral medication, for treating transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and severe heart disorder.
ATTR-CM is characterized by the accumulation of defective transthyretin proteins in the heart, leading to significant health risks for affected individuals.

FDA Approves BridgeBio's Attruby for Rare Heart Condition ATTR-CM

The FDA has approved BridgeBio's Attruby, offering a new treatment option for ATTR-CM, a rare heart condition, challenging Pfizer's previous dominance in this therapeutic area.
Research indicates that healthy breast cells may exhibit genetic changes similar to invasive breast cancer, raising concerns about diagnostic accuracy in breast cancer screening.

FDA Approves BridgeBio's Acoramidis (ATTRUBY) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved acoramidis (ATTRUBY), an oral transthyretin stabilizer, for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, aiming to reduce cardiovascular death and hospitalization.
Approval was based on the Phase 3 ATTRibute-CM study, which demonstrated significant reductions in mortality and cardiovascular hospitalizations, along with improved patient quality of life.

FDA Approves BridgeBio's Attruby for Rare Heart Condition, Challenging Pfizer's Vyndaqel

The FDA has approved BridgeBio's Attruby, a novel treatment for a rare heart condition, marking a significant advancement in cardiomyopathy treatments.
Studies suggest healthy breast cells may possess genetic traits leading to invasive breast cancer, prompting a re-examination of diagnostic norms.

FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM

The FDA has approved Attruby (acoramidis) from BridgeBio, marking the first new treatment in over five years for transthyretin amyloid cardiomyopathy (ATTR-CM).
ATTR-CM, affecting over 400,000 globally, results from misfolded protein deposits in the heart, leading to impaired function and, without treatment, death within five years of diagnosis.

BridgeBio's Attruby Receives FDA Approval for ATTR-CM Treatment

The FDA has approved BridgeBio's Attruby (acoramidis) for treating adults with transthyretin amyloid cardiomyopathy (ATTR-CM), marking a significant milestone for the company.
Attruby is the first and only approved product with a label specifying near-complete stabilization of transthyretin, demonstrating benefits on cardiovascular outcomes.

Health Canada Grants Priority Review to Biogen's Omaveloxolone for Friedreich's Ataxia

Health Canada has accepted Biogen's New Drug Submission for omaveloxolone under priority review for treating Friedreich's ataxia in patients aged 16 and older.
Omaveloxolone, a once-daily oral medication, could become the first disease-specific treatment option available for this rare and debilitating neuromuscular condition.

FDA Approves Roche's Subcutaneous Multiple Sclerosis Treatment and Eli Lilly's Eczema Drug

The FDA has approved Roche's subcutaneous injection for multiple sclerosis, offering an alternative to intravenous administration and potentially expanding treatment options.
Eli Lilly's new eczema drug has received FDA approval for use in adults and children over 12, providing a new therapeutic option for this patient population.

Reference News

[1]
Breaking Health News: FDA Approves Drug for Rare Heart Condition and More
devdiscourse.com · Nov 24, 2024

BridgeBio secures FDA approval for ATTR-CM drug; Canadian physicians report first clade I mpox case; WHO keeps mpox as p...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy